Market Size of MEA Uterine Cancer Therapeutics & Diagnostics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.70 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
MEA Uterine Cancer Therapeutics & Diagnostics Market Analysis
The Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market is expected to grow with a CAGR of 5.7% during the forecasted period. The key factors propelling the growth of this market are rise in awareness about uterine diseases and their available therapies, increasing health care expenditure in drug development, and subsequent technological advancements.
In South Africa, the Cancer Association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer in the country. Its mission involves providing research with regards to lowering cancer risk, educating the public regarding symptoms, screening and risk reduction, and providing care and support to all those affected by cancer. Furthermore, the department of Health in South Africa implemented programs to improve the health of women, all these programs is expected to increase early diagnosis procedures in near future.
As per National Clinical Trials (NCT) Registry, as of June 18, 2020, in Saudi Arabia "ASPIRE" clinical trial which is under phase II development for the treatment of endometrial cancer with stereotactic ablative radiation (SABR/SBRT) therapy. In near future, if trial shows positive outcome then it will boost the market as new therapy can be expected in coming years.
Therefore, these initiatives and research efforts are expected to boost the market in the region, in future.
MEA Uterine Cancer Therapeutics & Diagnostics Industry Segmentation
As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.
| By Cancer Type | |
| Endometrial Adenocarcinoma | |
| Adenosquamous Carcinoma | |
| Papillary Serous Carcinoma | |
| Uterine Sarcoma |
| By Product | |||||||
| |||||||
|
| Geography | |||||
|
MEA Uterine Cancer Therapeutics & Diagnostics Market Size Summary
The Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market is poised for significant growth, driven by increased awareness of uterine diseases and advancements in available therapies. The region is witnessing a rise in healthcare expenditure focused on drug development, which is further propelling market expansion. Initiatives such as those by the Cancer Association of South Africa and the Department of Health are enhancing public education on cancer symptoms and risk reduction, thereby improving early diagnosis procedures. Additionally, clinical trials in countries like Saudi Arabia and Israel are exploring new treatment modalities, which, if successful, are expected to introduce innovative therapies and boost market dynamics.
The growing incidence of endometrial adenocarcinoma, largely attributed to rising obesity rates among women, is a key factor driving the market. The early onset of symptoms associated with endometrial cancer facilitates timely diagnosis, thereby increasing the demand for diagnostic procedures. Clinical trials, such as those conducted by Merck Sharp & Dohme Corp, are underway to evaluate new therapies, which could further stimulate market growth. Despite the competitive landscape dominated by global players, technological advancements are enabling smaller companies to penetrate the market and capture a share. This competitive environment is expected to foster innovation and growth in the uterine cancer therapeutics and diagnostics sector across the region.
MEA Uterine Cancer Therapeutics & Diagnostics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies
-
1.2.2 Increasing Health Care Expenditure in Drug Development and Subsequent Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Low Success Rate in Clinical Trials for Cancer Drugs
-
1.3.2 High Cost Associated With the Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Cancer Type
-
2.1.1 Endometrial Adenocarcinoma
-
2.1.2 Adenosquamous Carcinoma
-
2.1.3 Papillary Serous Carcinoma
-
2.1.4 Uterine Sarcoma
-
-
2.2 By Product
-
2.2.1 Therapeutics
-
2.2.1.1 Surgery
-
2.2.1.2 Immunotherapy
-
2.2.1.3 Radiation Therapy
-
2.2.1.4 Chemotherapy
-
2.2.1.5 Others Therapeutics
-
-
2.2.2 Diagnostics
-
2.2.2.1 Biopsy
-
2.2.2.2 Pelvic Ultrasound
-
2.2.2.3 Hysteroscopy
-
2.2.2.4 Dilation and Curettage
-
2.2.2.5 CT Scan
-
-
-
2.3 Geography
-
2.3.1 Middle-East & Africa
-
2.3.1.1 GCC
-
2.3.1.2 South Africa
-
2.3.1.3 Rest of Middle-East & Africa
-
-
-
MEA Uterine Cancer Therapeutics & Diagnostics Market Size FAQs
What is the current MEA Uterine Cancer Therapeutics & Diagnostics Market size?
The MEA Uterine Cancer Therapeutics & Diagnostics Market is projected to register a CAGR of 5.70% during the forecast period (2024-2029)
Who are the key players in MEA Uterine Cancer Therapeutics & Diagnostics Market?
Abbott Laboratories, Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Siemens Healthcare Inc and F. Hoffmann-La Roche Ltd are the major companies operating in the MEA Uterine Cancer Therapeutics & Diagnostics Market.
